Radiation Changes Do Not Interfere With Postchemoradiation Restaging of Patients With Rectal Cancer by FDG PET/CT Before Curative Surgical Therapy

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 1, 2009, Pages 60-66

  Kalff, Victor ^a,b   Ware, Robert ^a   Heriot, Alexander ^a   Chao, Michael ^a   Drummond, Elizabeth ^a   Hicks, Rodney J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Chemoradiation; FDG PET CT; Radiation proctitis; Rectal Cancer; Surgery

Indexed keywords

CHEMORADIATION; CLINICAL REPORTING; CONFIDENCE INTERVALS; FDG PET/CT; FLUORO-DEOXYGLUCOSE; NORMAL TISSUES; POSITIVE PREDICTIVE VALUES; POSITRON EMISSIONS; RADIATION CHANGES; RECTAL CANCER; REFERENCE STANDARDS; SURGICAL THERAPIES;

DIAGNOSTIC RADIOGRAPHY; FLUORESCENT SCREENS; PATTERN RECOGNITION; POSITRON ANNIHILATION SPECTROSCOPY; SURGERY; TELEVISION PICTURE TUBES;

POSITRON EMISSION TOMOGRAPHY;

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROCTITIS; RECTUM CANCER; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

COMBINED MODALITY THERAPY; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEOPLASM STAGING; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROCTITIS; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 64049094317     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.06.1944     Document Type: Article

References (27)

1. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 336 (1997) 980-987
2. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
3. Madoff R.D., and Dykes S.L. What's new in colon and rectal surgery. J Am Coll Surg 198 (2004) 91-104
4. Amthauer H., Denecke T., Rau B., et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: Correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 31 (2004) 811-819
5. Guillem J.G., Moore H.G., Akhurst T., et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: A means for determining longterm outcomes of rectal cancer. J Am Coll Surg 199 (2004) 1-7
6. Calvo F.A., Domper M., Matute R., et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 58 (2004) 528-535
7. Kalff V., Duong C., Drummond E.G., et al. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med 47 (2006) 14-22
8. Denecke T., Rau B., Hoffmann K.T., et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: Is there a benefit in using functional imaging?. Eur Radiol 15 (2005) 1658-1666
9. Oku S., Nakagawa K., Momose T., et al. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med 16 (2002) 409-416
10. Anderson C., Koshy M., Staley C., et al. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys 69 (2007) 155-162
11. Quon A., Fischbein N.J., McDougall I.R., et al. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med 48 Suppl 1 (2007) 58S-67S
12. Kasamon Y.L., Jones R.J., and Wahl R.L. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 48 Suppl 1 (2007) 19S-27S
13. Kim S.Y., Lee S.W., Nam S.Y., et al. The Feasibility of 18F-FDG PET scans 1 month after completing radiotherapy of squamous cell carcinoma of the head and neck. J Nucl Med 48 (2007) 373-378
14. Hicks R.J., Mac Manus M.P., Matthews J.P., et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: Inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60 (2004) 412-418
15. DCTD N, NIH,DHHS. Cancer therapy evaluation program, common terminology criteria for adverse events, Version 3.0; 2003.
16. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 47 (2000) 13-47
17. Weber W.A. Use of PET for Monitoring Cancer Therapy and for Predicting Outcome. J Nucl Med 46 (2005) 983-995
18. Chessin D.B., Kiran R.P., Akhurst T., et al. The emerging role of 18F-fluorodeoxyglucose positron emission tomography in the management of primary and recurrent rectal cancer. J Am Coll Surg 201 (2005) 948-956
19. Kristiansen C., Loft A., Berthelsen A.K., et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum 51 (2008) 21-25
20. Ware R.E., Matthews J.P., Hicks R.J., et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck 26 (2004) 1008-1017
21. Duong C.P., Hicks R.J., Weih L., et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging 33 (2006) 770-778
22. Gerard J.P., Chapet O., Nemoz C., et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon R0-04 Phase II trial. J Clin Oncol 21 (2003) 1119-1124
23. Hofheinz R.D., von Gerstenberg-Helldorf B., Wenz F., et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 23 (2005) 1350-1357
24. Kendal W.S., Jonker D., Stern H., et al. Acute proctocolitis with commencement of neoadjuvant chemoradiation for rectal cancer. Am J Clin Oncol 29 (2006) 534-535
25. Hellwig D., Graeter T.P., Ukena D., et al. 18F-FDG PET for mediastinal staging of lung cancer: Which SUV threshold makes sense?. J Nucl Med 48 (2007) 1761-1766
26. Larson S.M., Erdi Y., Akhurst T., et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2 (1999) 159-171
27. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 19 (2001) 414-419